1. Home
  2. PVL vs ACRV Comparison

PVL vs ACRV Comparison

Compare PVL & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

HOLD

Current Price

$1.66

Market Cap

59.4M

Sector

Energy

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.96

Market Cap

67.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVL
ACRV
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medicinal Chemicals and Botanical Products
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.4M
67.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
PVL
ACRV
Price
$1.66
$1.96
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
65.1K
415.4K
Earning Date
03-20-2026
05-08-2026
Dividend Yield
7.43%
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
$26.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$1.20
52 Week High
$2.04
$3.56

Technical Indicators

Market Signals
Indicator
PVL
ACRV
Relative Strength Index (RSI) 35.33 65.74
Support Level $1.61 $1.62
Resistance Level $1.91 $2.02
Average True Range (ATR) 0.05 0.12
MACD -0.00 0.05
Stochastic Oscillator 32.00 74.07

Price Performance

Historical Comparison
PVL
ACRV

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: